Corporate finance Project Corporate finance Project Sun pharmaceuticals Sun pharmaceuticals Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Type | Public | Traded as | BSE : 524715 NSE: sunpharma | Industry | Pharmaceuticals | Founded | 1983
Premium Pharmaceutical industry Pharmacology
HRM CASE STUDY ON NATIONAL PHARMA Strengths of the analysis of the Discussant 1 • Highlighted the interests and gains of various stakeholders • Highlighted the various deficiencies in execution of the program • Breaking up of problems into appropriate sections : right to information‚ right to be consulted and right to decide jointly • Emphasized the fact that proper research has not been done and how the strategy has been forced by the top management Strengths of the analysis of the Discussant
Premium Management Scientific method Feedback
KALYAN PHARMA LIMITED- CASE ANALYSIS PHARMA SECTOR BACKGROUND: In early 1930’s the medicines were dispensed by doctors and the concept of prescription was not present. Later on the prescription segment grew to 80% by 1970’s and the reason being that number of doctors increased to 250000 as opposed to 110000. Presently the sector is growing at the rate of 8% to 9%. Sales of products has increased from 70 billion to 150 billion. COMPANY BACKGROUND: In 1907‚ Kalyan Pharma Limited (KPL) was
Premium Marketing Sales
L. van der Broek Consumer Care G. Balkema Portfolio Management R. Scheitza* Medical Care A. Main Research A. Klausener Development F. J. Placke Industrial Operations & QHSE A. Noack Bayer Schering Pharma (BSP) A. Fibig BSP Regions International U. Köstlin BSP Global Drug Discovery A. Busch* BSP Global Development K. Malik Central Administration & Organization M. Vehreschild Product Supply H. Klusik S. E. Peterson
Premium Board of directors
Company Background Square Pharmaceuticals Limited has been a household name in Bangladesh since 1958 when it started its operations as a partnership‚ getting incorporated in 1964 and finally getting listed at the stock exchange in 1995. The company has been in the leading front of innovation‚ and continues to introduce new and better medicines in the market every year. Today the 97% of the demands for medicine in the domestic market is catered to by the local pharmaceuticals company and Square
Premium Financial ratios Financial ratio Revenue
assist with my requests for information‚ as well as for his guidance and valuable assistance from the offset of this project. His insights and remarks were of great value. I have furthermore to thank Mr. Ashish Dixit ‚ Senior Executive “GLAXO pharma” who gave and confirmed this permission and encouraged me to go ahead with my thesis. I am bound to thank other staff members for their stimulating support. I am deeply indebted to my Faculty Guide Dr. Nidhi Mathur whose help‚ stimulating suggestions
Premium Pharmaceutical industry Generic drug
STRATEGIC GROUP THEORY: REVIEW‚ EXAMINATION AND APPLICATION IN THE UK PHARMACEUTICAL INDUSTRY by Graham Leask & David Parker Graham Leask‚ Aston Business School‚ Aston University‚ Birmingham B4 7ET‚ UK and David Parker‚ Cranfield School of Management‚ Cranfield University‚ Bedfordshire MK43 0AL‚ UK ACKNOWLEDGMENT The authors would like to acknowledge the valuable assistance of IMS Health in the preparation of this manuscript‚ in particular the assistance of Alan Johnson‚ and the helpful
Premium Strategic management Management
National Institute of Business Management Ist Floor‚ Swathandrya Samara Smrithi Bhavan‚ Nandavanam Road Palayam P.O. Trivandrum – 695 033 E-mail: admin@nibmglobal.com 0471- 4014294‚ 4014298 Assignments of One Year MBA / Two Year MBA/ One Year Executive MBA Semester - I 1. Students are requested to go through the instructions carefully. 2. The Assignment is a part of the internal assessment. 3. Marks will be awarded for each Assignment‚ which will be added to the total marks. Assignments
Premium Human resource management Management Human resources
Analysis of Indian Pharmaceutical Industry Dr. Reddy Laboratories Table of Contents Acknowledgement 4 1. Industry Analysis 5 1.1 Porter’s Five Forces Analysis 5 2. DRL’s Present Strategy 6 2.1Riding on Generics 6 2.2Focusing on depth rather than breadth 7 2.3 Leveraging strategic partnerships to reduce risk and investment 8 2.4 Para IV filings 9 2.5 Focusing on selected therapeutic areas 9 3. Key Issues faced by DRL 10 3.1 Poor positioning in India 10 3.2 Russian Opportunity
Premium Generic drug Pharmaceutical industry
SQUARE PHARMACEUTICALS LIMITED Mission Our Mission is to produce and provide quality & innovative healthcare relief for people‚ maintain stringently ethical standard in business operation also ensuring benefit to the shareholders‚ stakeholders and the society at large. Vision We view business as a means to the material and social wellbeing of the investors‚ employees and the society at large‚ leading to accretion of wealth through financial and moral gains as a part of the process of the
Premium Inventory Financial ratio Financial ratios